DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Johnson - 1 Brendan McDermid - 1 J - 1 Judge Page Kelley - 1 Antoni Nargol - 1 David Langton - 1 Lara Montecalvo - 1 Montecalvo - 1
Top related locs:
New York U.S Boston Texas Nargol United States 1st
Top related orgs:
Johnson - 1 New York Stock Exchange - 1 REUTERS - 1 1st U.S - 1 Circuit - 1 Appeals - 1 Inc - 1 U.S . Food - 1

Search resuls for: "DePuy"


2 mentions found


☆ J&J secures dismissal of whistleblower case over misuse of confidential info
  + stars: | 2023-06-01 | by ( Brendan Pierson | ) www.reuters.com   time to read: +3 min
FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. Montecalvo was joined by Chief Judge David Barron and Circuit Judge Kermit Lipez. The devices became the subject of more than 10,000 product liability lawsuits consolidated before a federal judge in Texas. Circuit Court of Appeals, No. For plaintiffs: Ross Morrison of YankwittFor J&J: Adam Tarosky of Nixon PeabodyRead more:J&J hip implant whistleblower case tossed over confidential info misuse
Persons: Johnson, Brendan McDermid, J, Judge Page Kelley, Antoni Nargol, David Langton, Lara Montecalvo, Montecalvo, David Barron, Kermit Lipez, Langton, DePuy, Nargol, Ross Morrison, Yankwitt, Adam Tarosky, Nixon Peabody Read Organizations: Reuters, Johnson, New York Stock Exchange, REUTERS, 1st U.S, Circuit, Appeals, Inc, U.S . Food, Drug Administration, & $ Locations: New York, U.S, Boston, Texas, Nargol, United States, 1st
☆ Regulatory approvals for AbbVie, J&J bolster the Club investment case
  + stars: | 2022-10-20 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +5 min
The technology platform — called Teligen — was developed by DePuy Synthes, a J & J subsidiary under the medical technology umbrella. J & J said Thursday it expects Teligen to be available in the U.S. later this year. J & J CEO Joaquin Duato, who took over the role earlier this year, has spoken about the complementary nature of the med tech and pharmaceutical divisions. That's where Johnson & Johnson is going to play, in that intersection. We like owning J & J for its defensive characteristics right now, while all three divisions are under the same roof.
0 next >>
Total: 2